These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8011967)

  • 1. Bioavailability and reversible metabolism of prednisone and prednisolone in man.
    Garg V; Jusko WJ
    Biopharm Drug Dispos; 1994 Mar; 15(2):163-72. PubMed ID: 8011967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonlinear pharmacokinetics and interconversion of prednisolone and prednisone in rats.
    Huang ML; Jusko WJ
    J Pharmacokinet Biopharm; 1990 Oct; 18(5):401-21. PubMed ID: 2266496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of thyroid dysfunction on prednisolone and prednisone interconversion and disposition in the rat.
    Murata R; Haughey DB; Jusko WJ
    Drug Metab Dispos; 1990; 18(4):403-8. PubMed ID: 1976060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic parameters of prednisone and prednisolone in healthy volunteers].
    Etienne SD; Vandermeersch V; Chosidow O; Vu-Thi-My-Le C; Godeau P; Diquet B; Herson S
    Ann Med Interne (Paris); 1990; 141(6):507-11. PubMed ID: 2285202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses.
    Ferry JJ; Horvath AM; Bekersky I; Heath EC; Ryan CF; Colburn WA
    J Clin Pharmacol; 1988 Jan; 28(1):81-7. PubMed ID: 3350994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic comparison of two oral liquid glucocorticoid formulations.
    Kamada AK; Wiener MB; LaVallee NM; Scott MB; Selner JC; Szefler SJ
    Pharmacotherapy; 1997; 17(2):353-6. PubMed ID: 9085328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose dependent pharmacokinetics of prednisone and prednisolone in man.
    Rose JQ; Yurchak AM; Jusko WJ
    J Pharmacokinet Biopharm; 1981 Aug; 9(4):389-417. PubMed ID: 7310640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.
    Rose JQ; Yurchak AM; Meikle AW; Jusko WJ
    J Pharmacokinet Biopharm; 1981 Feb; 9(1):1-14. PubMed ID: 7229914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednisone and prednisolone bioavailability in renal transplant patients.
    Gambertoglio JG; Frey FJ; Holford NH; Birnbaum JL; Lizak PS; Vincenti F; Feduska NJ; Salvatierra O; Amend WJ
    Kidney Int; 1982 Apr; 21(4):621-6. PubMed ID: 7047863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of prednisone and prednisolone.
    Pickup ME
    Clin Pharmacokinet; 1979; 4(2):111-28. PubMed ID: 378499
    [No Abstract]   [Full Text] [Related]  

  • 11. Reversible metabolism and pharmacokinetics: application to prednisone-prednisolone.
    Wagner JG; DiSanto AR; Gillespie WR; Albert KS
    Res Commun Chem Pathol Pharmacol; 1981 Jun; 32(3):387-405. PubMed ID: 7268190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone.
    Garg V; Blum R; Wilner KD; Jusko WJ
    J Clin Pharmacol; 1992 Mar; 32(3):222-30. PubMed ID: 1564126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability assessment of a liquid prednisone preparation.
    Georgitis JW; Flesher KA; Szefler SJ
    J Allergy Clin Immunol; 1982 Oct; 70(4):243-7. PubMed ID: 7119300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednisolone clearance: a possible determinant for glucocorticoid efficacy in patients with oral vesiculo-erosive diseases.
    Lozada F; Frey FJ; Benet LZ
    J Dent Res; 1983 May; 62(5):575-7. PubMed ID: 6573375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ketoconazole on the metabolism of prednisolone.
    Zürcher RM; Frey BM; Frey FJ
    Clin Pharmacol Ther; 1989 Apr; 45(4):366-72. PubMed ID: 2639662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma.
    Xu J; Winkler J; Derendorf H
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):355-72. PubMed ID: 17318442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies comparing the metabolic clearance rate of 11 beta,17,21-trihydroxypregn-1,4-diene-3,20-dione (prednisolone) after oral 17,21-dihydroxypregn-1,4-diene-3,11,20-trione and intravenous prednisolone.
    Hsueh WA; Paz-Guevara A; Bledsoe T
    J Clin Endocrinol Metab; 1979 May; 48(5):748-52. PubMed ID: 429520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered prednisolone pharmacokinetics in patients with cystic fibrosis.
    Dove AM; Szefler SJ; Hill MR; Jusko WJ; Larsen GL; Accurso FJ
    J Pediatr; 1992 May; 120(5):789-94. PubMed ID: 1578318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects.
    Schwartz JI; Mukhopadhyay S; Porras AG; Viswanathan-Aiyer KJ; Adcock S; Ebel DL; Gertz BJ
    J Clin Pharmacol; 2003 Feb; 43(2):187-92. PubMed ID: 12616672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of prednisolone and endogenous cortisol suppression in the elderly.
    Stuck AE; Frey BM; Frey FJ
    Clin Pharmacol Ther; 1988 Apr; 43(4):354-62. PubMed ID: 3356080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.